 Pauline Merrill
Concepts (89)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Uveitis, Posterior | 3 | 2020 | 3 | 1.320 |
Why?
| | Sirolimus | 3 | 2020 | 22 | 1.240 |
Why?
| | Posterior Eye Segment | 2 | 2020 | 2 | 1.070 |
Why?
| | Macular Edema | 1 | 2019 | 4 | 0.830 |
Why?
| | Immunologic Factors | 1 | 2019 | 47 | 0.800 |
Why?
| | Uveitis | 4 | 2018 | 7 | 0.680 |
Why?
| | Rickettsia Infections | 1 | 2016 | 1 | 0.670 |
Why?
| | Retinitis | 1 | 2016 | 3 | 0.670 |
Why?
| | Eye Infections, Bacterial | 1 | 2016 | 5 | 0.660 |
Why?
| | Visual Acuity | 5 | 2020 | 47 | 0.530 |
Why?
| | Panuveitis | 2 | 2020 | 2 | 0.430 |
Why?
| | Uveitis, Intermediate | 2 | 2020 | 2 | 0.430 |
Why?
| | Immunosuppressive Agents | 3 | 2020 | 167 | 0.410 |
Why?
| | Intravitreal Injections | 4 | 2020 | 8 | 0.350 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2020 | 524 | 0.290 |
Why?
| | Adrenal Cortex Hormones | 2 | 2016 | 99 | 0.280 |
Why?
| | Double-Blind Method | 3 | 2020 | 541 | 0.270 |
Why?
| | Vision Disorders | 2 | 2019 | 26 | 0.270 |
Why?
| | Tomography, Optical Coherence | 2 | 2020 | 20 | 0.260 |
Why?
| | Choroid Diseases | 1 | 2002 | 4 | 0.250 |
Why?
| | Retinal Diseases | 1 | 2002 | 9 | 0.250 |
Why?
| | Female | 10 | 2020 | 17657 | 0.250 |
Why?
| | Aged | 8 | 2020 | 9833 | 0.230 |
Why?
| | Electronic Health Records | 2 | 2019 | 72 | 0.230 |
Why?
| | Humans | 15 | 2020 | 29841 | 0.230 |
Why?
| | Intraocular Pressure | 1 | 2020 | 8 | 0.220 |
Why?
| | Databases, Factual | 2 | 2019 | 357 | 0.220 |
Why?
| | Uveitis, Anterior | 1 | 2019 | 5 | 0.210 |
Why?
| | Spondylarthropathies | 1 | 2019 | 9 | 0.210 |
Why?
| | Follow-Up Studies | 3 | 2020 | 2017 | 0.210 |
Why?
| | Anti-Inflammatory Agents | 2 | 2020 | 108 | 0.210 |
Why?
| | Middle Aged | 10 | 2020 | 11053 | 0.200 |
Why?
| | International Classification of Diseases | 1 | 2018 | 24 | 0.200 |
Why?
| | Academic Medical Centers | 1 | 2019 | 156 | 0.190 |
Why?
| | Retinal Necrosis Syndrome, Acute | 2 | 2008 | 2 | 0.170 |
Why?
| | Retina | 1 | 2016 | 17 | 0.170 |
Why?
| | Rickettsia | 1 | 2016 | 1 | 0.170 |
Why?
| | Chorioretinitis | 1 | 2016 | 3 | 0.170 |
Why?
| | HLA-A Antigens | 1 | 2016 | 13 | 0.170 |
Why?
| | Africa | 1 | 2016 | 12 | 0.170 |
Why?
| | Travel | 1 | 2016 | 15 | 0.160 |
Why?
| | Retinal Neoplasms | 1 | 2013 | 1 | 0.140 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2013 | 49 | 0.140 |
Why?
| | Lymphoma | 1 | 2013 | 57 | 0.140 |
Why?
| | Male | 8 | 2020 | 17153 | 0.130 |
Why?
| | Retrospective Studies | 5 | 2020 | 3303 | 0.130 |
Why?
| | Ocular Hypotension | 1 | 2012 | 1 | 0.130 |
Why?
| | Adult | 7 | 2020 | 9591 | 0.120 |
Why?
| | Antineoplastic Agents | 1 | 2013 | 314 | 0.110 |
Why?
| | Time Factors | 3 | 2020 | 1894 | 0.100 |
Why?
| | Eye Infections, Viral | 1 | 2008 | 2 | 0.100 |
Why?
| | Drug Resistance, Viral | 1 | 2008 | 43 | 0.090 |
Why?
| | AIDS-Related Opportunistic Infections | 1 | 2008 | 49 | 0.090 |
Why?
| | Treatment Outcome | 4 | 2020 | 3788 | 0.090 |
Why?
| | Young Adult | 3 | 2020 | 2198 | 0.080 |
Why?
| | Vasculitis, Central Nervous System | 1 | 2004 | 3 | 0.080 |
Why?
| | Magnetic Resonance Angiography | 1 | 2004 | 51 | 0.070 |
Why?
| | Prevalence | 2 | 2019 | 533 | 0.070 |
Why?
| | Risk Factors | 2 | 2019 | 2549 | 0.070 |
Why?
| | Aged, 80 and over | 3 | 2020 | 5016 | 0.060 |
Why?
| | Exudates and Transudates | 1 | 2002 | 1 | 0.060 |
Why?
| | Remission, Spontaneous | 1 | 2002 | 11 | 0.060 |
Why?
| | Injections, Subcutaneous | 1 | 2020 | 44 | 0.060 |
Why?
| | Women's Health | 1 | 2002 | 215 | 0.050 |
Why?
| | Delayed Diagnosis | 1 | 2019 | 13 | 0.050 |
Why?
| | Computer Systems | 1 | 2018 | 6 | 0.050 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2018 | 39 | 0.050 |
Why?
| | Adolescent | 2 | 2016 | 2591 | 0.040 |
Why?
| | Predictive Value of Tests | 1 | 2019 | 617 | 0.040 |
Why?
| | Sensitivity and Specificity | 1 | 2018 | 592 | 0.040 |
Why?
| | Clinical Trials as Topic | 1 | 2018 | 382 | 0.040 |
Why?
| | Disease-Free Survival | 1 | 2016 | 245 | 0.040 |
Why?
| | Chicago | 1 | 2019 | 916 | 0.040 |
Why?
| | Treatment Failure | 1 | 2016 | 186 | 0.040 |
Why?
| | Prognosis | 1 | 2019 | 1025 | 0.040 |
Why?
| | Reproducibility of Results | 1 | 2018 | 857 | 0.040 |
Why?
| | Acute Disease | 1 | 2016 | 272 | 0.040 |
Why?
| | Animals | 2 | 2018 | 5125 | 0.040 |
Why?
| | Evidence-Based Medicine | 1 | 2016 | 233 | 0.040 |
Why?
| | Diagnosis, Differential | 1 | 2016 | 466 | 0.040 |
Why?
| | Chronic Disease | 1 | 2016 | 530 | 0.040 |
Why?
| | African Continental Ancestry Group | 1 | 2012 | 172 | 0.030 |
Why?
| | Acyclovir | 1 | 2008 | 6 | 0.020 |
Why?
| | Ganciclovir | 1 | 2008 | 26 | 0.020 |
Why?
| | Immunocompromised Host | 1 | 2008 | 51 | 0.020 |
Why?
| | Prednisone | 1 | 2008 | 76 | 0.020 |
Why?
| | Drug Therapy, Combination | 1 | 2008 | 264 | 0.020 |
Why?
| | European Continental Ancestry Group | 1 | 2012 | 593 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2012 | 1220 | 0.020 |
Why?
|
|
Merrill's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|